Cargando…
Eltrombopag – a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations
Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune thrombocytopenia (ITP). Rather than preventing destruction of platelets, these agents increase the production of platelets, presumably overwhelming the immune system resulting in normal...
Autores principales: | Cook, Lucy, Cooper, Nichola |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2915538/ https://www.ncbi.nlm.nih.gov/pubmed/20689640 |
Ejemplares similares
-
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Rice, Lawrence
Publicado: (2009) -
Comparison of Splenectomy and Eltrombopag Treatment in the Second-Line Treatment of Immune Thrombocytopenic Purpura
por: Uğur, Mehmet Can, et al.
Publicado: (2021) -
Eltrombopag-Induced Thrombocytosis and Thrombosis in Patients With Antiphospholipid Syndrome and Immune Thrombocytopenic Purpura
por: Oo, Zayar, et al.
Publicado: (2022) -
Eltrombopag for Adults and Children with Immune-Refractory Thrombocytopenic Purpura: A Systematic Review
por: de Barros Torelli, Danielle Francisco Honorato, et al.
Publicado: (2023) -
Acute Myocardial Infarction Due to Eltrombopag Therapy in a Patient with Immune Thrombocytopenic Purpura
por: Sert, Sena, et al.
Publicado: (2017)